Quick Answer
Acumen Pharmaceuticals, Inc. reported Net Income of -$121.33 million for fiscal year 2025.
Acumen Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$121.33M -18.6% |
-$102.33M -95.4% |
-$52.37M -22.2% |
-$42.86M +57.4% |
-$100.61M -1273.5% |
-$7.33M |
| Diluted EPS | -$2.00 -17.0% |
-$1.71 -58.3% |
-$1.08 -1.9% |
-$1.06 +78.9% |
-$5.02 | — |
| Total Assets | $122.83M -48.6% |
$238.99M -22.9% |
$310.12M +57.8% |
$196.59M -14.6% |
$230.33M +418.4% |
$44.43M |
| Cash and Equivalents | $53.99M +51.5% |
$35.63M -46.7% |
$66.89M -48.6% |
$130.10M +6.5% |
$122.16M +179.1% |
$43.78M +568.1% |
| Long-Term Debt | $22.40M -23.9% |
$29.42M -1.6% |
$29.90M | $0.00 | — | — |
| Stockholders Equity | $70.43M -61.3% |
$181.82M -31.9% |
$266.97M +41.4% |
$188.78M -16.2% |
$225.18M +1311.2% |
-$18.59M -62.8% |
| R&D Expense | $104.89M +11.8% |
$93.80M +121.7% |
$42.32M +30.8% |
$32.36M +163.0% |
$12.30M +53.9% |
$8.00M |
| Operating Income | -$123.83M -8.6% |
-$114.02M -86.5% |
-$61.14M -35.2% |
-$45.24M -131.0% |
-$19.58M -147.5% |
-$7.91M |
| Shares Outstanding | 60.58M +0.8% |
60.09M +3.8% |
57.91M +41.2% |
41.03M +1.4% |
40.47M +9556.6% |
419,124 |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$26.45M | +11.1% | +35.4% |
| Diluted EPS | September 30, 2025 | -$0.44 | +12.0% | +35.3% |
| Total Assets | September 30, 2025 | $142.22M | -46.7% | -17.3% |
| Cash and Equivalents | September 30, 2025 | $46.83M | +41.1% | +27.2% |
| Long-Term Debt | September 30, 2025 | $27.05M | -8.8% | -9.5% |
| Stockholders Equity | September 30, 2025 | $93.17M | -57.1% | -20.4% |
| R&D Expense | September 30, 2025 | $21.97M | -19.4% | -40.8% |
| Operating Income | September 30, 2025 | -$26.51M | +17.8% | +36.5% |
| Shares Outstanding | September 30, 2025 | 60.57M | +0.8% | +0.0% |
- Acumen Pharmaceuticals, Inc. reported Net Income of -$121.33 million for fiscal year 2025.
- Acumen Pharmaceuticals, Inc. showed a decrease of -18.6% in Net Income compared to the prior fiscal year.
- Acumen Pharmaceuticals, Inc. reported Diluted EPS of $2.00 per share (loss) for fiscal year 2025.
- Acumen Pharmaceuticals, Inc. showed a decrease of -17.0% in Diluted EPS compared to the prior fiscal year.
- Acumen Pharmaceuticals, Inc. reported Total Assets of $122.83 million for fiscal year 2025.
- Acumen Pharmaceuticals, Inc. showed a decrease of -48.6% in Total Assets compared to the prior fiscal year.
- Acumen Pharmaceuticals, Inc. reported Cash and Equivalents of $53.99 million for fiscal year 2025.
- Acumen Pharmaceuticals, Inc. showed an increase of +51.5% in Cash and Equivalents compared to the prior fiscal year.
- Acumen Pharmaceuticals, Inc. reported Long-Term Debt of $22.40 million for fiscal year 2025.
- Acumen Pharmaceuticals, Inc. showed a decrease of -23.9% in Long-Term Debt compared to the prior fiscal year.
- Acumen Pharmaceuticals, Inc. reported Stockholders Equity of $70.43 million for fiscal year 2025.
- Acumen Pharmaceuticals, Inc. showed a decrease of -61.3% in Stockholders Equity compared to the prior fiscal year.
- Acumen Pharmaceuticals, Inc. reported R&D Expense of $104.89 million for fiscal year 2025.
- Acumen Pharmaceuticals, Inc. showed an increase of +11.8% in R&D Expense compared to the prior fiscal year.
- Acumen Pharmaceuticals, Inc. reported Operating Income of -$123.83 million for fiscal year 2025.
- Acumen Pharmaceuticals, Inc. showed a decrease of -8.6% in Operating Income compared to the prior fiscal year.
- Acumen Pharmaceuticals, Inc. reported Shares Outstanding of 60.58 million shares for fiscal year 2025.
- Acumen Pharmaceuticals, Inc. showed an increase of +0.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: